Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.

Axel U DignassBritta SiegmundRalf GoertzGundula SchneidewindLena Fanter

Published in: Scandinavian journal of gastroenterology (2019)

This analysis indicates that vedolizumab has comparable efficacy to adalimumab with improved safety in biologic-naïve patients with moderate to severe UC.

Keyphrases

ulcerative colitis
rheumatoid arthritis
early onset
high intensity
hiv infected
disease activity
juvenile idiopathic arthritis
hidradenitis suppurativa